Clinical Trial Update: Study of BMS-587101 in Patients With Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 study of BMS-587101 in patients with moderate to severe psoriasis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BMS-587101

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis, Moderate to Severe | Phase 2 | Status: TERMINATED